Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Net Income towards Common Stockholders: 2010-2025

Historic Net Income towards Common Stockholders for Ligand Pharmaceuticals (LGND) over the last 16 years, with Sep 2025 value amounting to $117.3 million.

  • Ligand Pharmaceuticals' Net Income towards Common Stockholders rose 1735.15% to $117.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year increase of 7.38%. This contributed to the annual value of -$4.0 million for FY2024, which is 142.16% down from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Net Income towards Common Stockholders is $117.3 million, which was up 2,319.50% from $4.8 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of $117.3 million in Q3 2025 and a low of -$51.9 million during Q2 2024.
  • For the 3-year period, Ligand Pharmaceuticals' Net Income towards Common Stockholders averaged around $7.7 million, with its median value being -$1.7 million (2023).
  • Within the past 5 years, the most significant YoY rise in Ligand Pharmaceuticals' Net Income towards Common Stockholders was 5,273.51% (2024), while the steepest drop was 2,366.86% (2024).
  • Over the past 5 years, Ligand Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$2.2 million in 2021, then crashed by 32.75% to -$3.0 million in 2022, then skyrocketed by 716.33% to $18.2 million in 2023, then crashed by 270.93% to -$31.1 million in 2024, then skyrocketed by 1,735.15% to $117.3 million in 2025.
  • Its last three reported values are $117.3 million in Q3 2025, $4.8 million for Q2 2025, and -$42.5 million during Q1 2025.